Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I safety and pharmacokinetics study of AZD7442 in healthy Japanese adults
jRCT2071200111Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial in coronavirus disease 2019 (COVID-19) comparing AZD7442 with Saline placebo (2 arms). Primary endpoints: Safety and tolerability and Pharmacokinetics of AZD8895 and AZD1061. Started Mar 2021; status: completed.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071200111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200111.